English
Chinese
Cart
Reducing Total Cost Of Ownership
It's a tough question that every pharmaceutical company faces - how do you ensure quality and reliability of a drug product while reducing costs? The answer: Reduce total cost of ownership.
Issues like breakage and delamination can result in costly recalls. By selecting the proper containment and delivery system for your drug products early in the development process, you may be able to avoid these issues.
Through early partnership, West can help manage the cost of ownership through:
- Lifecycle Management
- Integrated containment and delivery
- Regulatory and Technical expertise
Case Studies
Read the following Case Studies to see how west can help:
Novapure® Components
Biopharmaceutical Company Selects West's Novapure® 1mL Long Plunger for First Commercial Drug Launch
Daikyo® Crystal Zenith® Solutions
Solving the challenge of High pH Injectable Drug Products
Daikyo® Crystal Zenith® Components
Solving Breakage for High-Volume Delivery
Daikyo® Crystal Zenith® Solutions
Avoid Delamination in Reconstituted Drug Products
Envision™ Verification
Minimizing Drug Shortages of Life Promoting Medicine
Envision™ Verification
Mitigating the risk of a drug recall
NovaPure® Components
Partnering to Ensure High Quality & Optimized Functional Performance Based on Quality by Design (QbD)
Newsworthy
May 18, 2021
NovaPure® 3mL Cartridge Components: Quality by Design (QbD) Principles Mitigate Risks Associated with Biologic Drugs Packaging and Delivery Systems
Globally, the market for biologic drugs is growing significantly, due to their proven ability to treat major chronic diseases, in particular those found among an increasingly aging population. Cartridge systems are very important in delivering these biologic drugs; they can be used in autoinjectors, pen injectors, and wearable devices. Since biologics drugs are very sensitive, they require highest-quality cartridge components.
January 13, 2021
The Power of Shared Knowledge: West Generics Virtual Panel Event Outlines Key Drivers and Best Practices in a Growing Market
The West Generics team recently hosted a virtual panel event featuring experts from pharmaceutical, supply chain and consulting backgrounds to discuss the trends, pressure points and best practices around generics with a goal of shared understanding around a growing market.
April 19, 2021
NovaPure® Components Answer Your Concerns over Particulates in Biologics
An enormous growth trend is being observed in the market for biologic drugs; they are being employed ever more frequently as treatments for chronic issues such as cancer and autoimmune diseases. This growth is reflected by the number of companies involved (established and emerging), and in the capital investment for manufacturing facilities for both biologics and biosimilars. Companies must apply a holistic approach to bringing a biologic drug to market.
May 18, 2021
NovaPure® 3mL Cartridge Components: Quality by Design (QbD) Principles Mitigate Risks Associated with Biologic Drugs Packaging and Delivery Systems
Globally, the market for biologic drugs is growing significantly, due to their proven ability to treat major chronic diseases, in particular those found among an increasingly aging population. Cartridge systems are very important in delivering these biologic drugs; they can be used in autoinjectors, pen injectors, and wearable devices. Since biologics drugs are very sensitive, they require highest-quality cartridge components.
January 13, 2021
The Power of Shared Knowledge: West Generics Virtual Panel Event Outlines Key Drivers and Best Practices in a Growing Market
The West Generics team recently hosted a virtual panel event featuring experts from pharmaceutical, supply chain and consulting backgrounds to discuss the trends, pressure points and best practices around generics with a goal of shared understanding around a growing market.
April 19, 2021
NovaPure® Components Answer Your Concerns over Particulates in Biologics
An enormous growth trend is being observed in the market for biologic drugs; they are being employed ever more frequently as treatments for chronic issues such as cancer and autoimmune diseases. This growth is reflected by the number of companies involved (established and emerging), and in the capital investment for manufacturing facilities for both biologics and biosimilars. Companies must apply a holistic approach to bringing a biologic drug to market.
Daikyo Crystal Zenith® is a registered trademark of Daikyo Seiko, Ltd.
NovaPure®, Envision™ and AccelTRA™ are registered trademarks or trademarks of West Pharmaceutical Services, Inc. in the United States and other jurisdictions.
NovaPure®, Envision™ and AccelTRA™ are registered trademarks or trademarks of West Pharmaceutical Services, Inc. in the United States and other jurisdictions.